These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26999067)

  • 1. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
    Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
    Malumbres M; Pérez de Castro I
    Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of mitotic interaction between the nucleoporin Tpr and aurora kinase A.
    Kobayashi A; Hashizume C; Dowaki T; Wong RW
    Cell Cycle; 2015; 14(9):1447-58. PubMed ID: 25789545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
    Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
    J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
    Liewer S; Huddleston A
    Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
    Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
    Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Interactions between the Aurora Kinases Reveal New Requirements for AURKB and AURKC during Oocyte Meiosis.
    Nguyen AL; Drutovic D; Vazquez BN; El Yakoubi W; Gentilello AS; Malumbres M; Solc P; Schindler K
    Curr Biol; 2018 Nov; 28(21):3458-3468.e5. PubMed ID: 30415701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition.
    Zhang Z; Zeng D; Zhang W; Chen A; Lei J; Liu F; Deng B; Zhuo J; He B; Yan M; Lei X; Wang S; Lam EW; Liu Q; Wang Z
    Cell Death Dis; 2021 Sep; 12(10):893. PubMed ID: 34593753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
    Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
    Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
    J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
    Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
    Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
    Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
    Zumbar CT; Usubalieva A; King PD; Li X; Mifsud CS; Dalton HM; Sak M; Urio S; Bryant WM; McElroy JP; Farmer G; Lehman NL
    J Neurooncol; 2018 May; 137(3):481-492. PubMed ID: 29396807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
    Alrifai D; Pettengell R
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.